A Short History of Topoisomerases at Actelion Pharmaceuticals
The discovery of novel antibacterials devoid of cross resistance is of utmost importance. At the same time, biological pathways and processes suitable to be targeted are limited. At Actelion Pharmaceuticals we decided to work on novel bacterial topoisomerase inhibitors (NBTI) to discover new antibi...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | deu |
| Published: |
Swiss Chemical Society
2022-08-01
|
| Series: | CHIMIA |
| Subjects: | |
| Online Access: | https://chimia.ch/chimia/article/view/6076 |